With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

CagriSema patients lost more weight than those taking either component alone: 20.4% for the combination vs 11.5% with cagrilintide, 14.9% with semaglutide, and 3% with placebo.

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. The two molecules induce weight loss by reducing hunger, ...

The 68-week study showed participants on CagriSema lost about 23% of their body weight, compared with 12% for those taking cagrilintide by itself, 16% for those on semaglutide, and 2.3% for people ...

CagriSema is a fixed-dosed combination of a long-acting amylin analogue, cagrilintide 2.4-milligram and semaglutide 2.4-mg doses, as opposed to other GLP-1 weight-loss drugs, like Ozempic and Wegovy.

The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group (estimated difference [95% CI] -20.4 [-21.1 to -19.7 ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

CagriSema was said to also have similar side effects as other GLP-1 drugs on the market – effects which include gastrointestinal discomfort. However, they diminished over time. Despite these ...

In December, in the REDEFINE 1 Phase 3 trial, CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and ...

The REDEFINE 1 trial found that treatment with CagriSema resulted in greater weight loss of 22.7% at 68 weeks versus 2.3% in the placebo group (estimated difference [95% CI] -20.4 [-21.1 to -19.7 ...